Triatomic Capital Q2 2025 investor letter (dated July 31, 2025) summarizing market observations and portfolio updates. Key themes: rapid evolution and fragmentation among foundational AI model providers, rising demand and constrained supply for compute/datacenter capacity, growing tooling that reduces switching costs, and a difficult policy/funding environment for life sciences (notably substantial NIH funding cuts and overhead cap). Fund update: Private I LP has 15 portfolio companies (10 core), sector allocation heavily weighted to engineered biology and next‑gen compute, active dealflow and several follow-on financings expected; AGM scheduled for Sept 11, 2025.

Questions this document answers

July 31, 2025

15 companies

10 core investments

31% engineered biology; 31% next‑gen compute; 22% automated economy; 10% engineered materials; 5% new energy

$44.4B

More from Jeff

PDF

Triatomic Q4 2024 Private.pdf

1mo ago
PDF

Triatomic Q3 2025 Private.pdf

1mo ago
PDF

Triatomic Q3 2024 Private.pdf

1mo ago
PDF

Triatomic Q2 2025 Private.pdf

1mo ago
PDF

Triatomic Q2 2024 Private.pdf

1mo ago
PDF

Triatomic Q1 2025 Private.pdf

1mo ago
PDF

Triatomic Q1 2024 - Private Fund.pdf

1mo ago
PDF

Triatomic Q4 2025 - Private.pdf

1mo ago
PDF

Triatomic Q2 2026 - Private I and II.pdf

1mo ago
PDF

Triatomic Q1 2026 - Private II.pdf

1mo ago
PDF

Triatomic Q1 2026 - Private I.pdf

1mo ago
See all content